Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why

Zacks Dec 27, 2024 22:30

With 49% Stake, Puma Biotechnology, Inc. (NASDAQ:PBYI) Seems to Have Captured Institutional Investors' Interest

Yahoo FinanceDec 24, 2024 02:50

Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results

BenzingaDec 23, 2024 22:04

Puma Biotechnology's NERLYNX Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer With a HER2 Mutation

BusinesswireDec 23, 2024 22:01

Express News | Puma Biotechnology’s Nerlynx® Included in Nccn Clinical Practice Guidelines for the Treatment of Cervical Cancer With a Her2 Mutation

BreakingsDec 23, 2024 22:01

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

BusinesswireDec 5, 2024 06:15